Within our efforts to develop GPC3-targeting radiotracers, we aimed to develop 68Ga- or 64Cu-labeled derivatives of TJ12P2 with improved tumor-to-liver contrast by identifying structure–activity relationships and investigating the human serum stability of the peptides. Here, GPC3 is linked to neoplasm.